MenACYW-TT booster vaccine immunogenic and well-tolerated in adults aged ≥59 years

According to a recent study, quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) booster dose was found to be immunogenic and well tolerated in participants aged ≥59 years, irrespective of previously received quadrivalent meningococcal vaccine. This study was published in the journal, Human vaccines & immunotherapeutics.

This 2-stage phase III randomized study included 401 older adults (≥59 years) who were primed with either MenACYW-TT or a quadrivalent meningococcal polysaccharide vaccine (MPSV4). During Stage I, the participants who had received either MPSV4 (n = 165) or MenACYW-TT (n = 236) 3 years before, were randomized in a 9:2 ratio to receive either the booster (MenACYW-TT) or to have blood drawn for persistence only. Those participants who were primed 6-7 years earlier with MPSV4 or MenACYW-TT, had blood drawn for antibody persistence only. Functional antibodies against each serogroup were measured at baseline and for those participants receiving a booster, it was measured 30 days post-vaccination (D30).

For all serogroups, the seroresponse rates at D30 ranged from 49.2% to 60.8% and 79.3 to 93.1% in the MPSV4-primed and MenACYW-TT-primed groups, respectively. It was found that MenACYW-TT induced adequate seroresponses in each primed group. After primary vaccination, geometric mean titers (GMTs) for serogroups C, W, and Y trended higher than pre-vaccination levels at both 3 and 6-7 years.

Based on the above results, it can be concluded that MenACYW-TT booster may be immunogenic and well tolerated in participants aged ≥59 years, who may elicit the greatest immune responses.